Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any Zimmermann-Laband syndrome in which the cause of the disease is a mutation in the KCNN3 gene. It is characterized by developmental delay, intellectual disability, coarse face, gingival hyperplasia, and nail hypoplasia/aplasia
Features include always present findings: Small nail, Broad nasal tip, and Global developmental delay; and common findings: Triphalangeal thumb, Coarse facial features, Hypertrichosis, and Long hallux and others. 30 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Arms and legs | 5 | Aplasia of distal finger phalanx, Short distal phalanx of finger, Absent toenail |
KCNN3 encodes potassium calcium-activated channel subfamily N member 3 (731 aa). Small conductance calcium-activated potassium channel that mediates the voltage-independent transmembrane transfer of potassium across the cell membrane through a constitutive interaction with calmodulin which binds the intracellular calcium allowing its opening. Highest expression in Cells EBV-transformed lymphocytes (19.3 TPM) and Brain Nucleus accumbens basal ganglia (11.1 TPM).
Zimmermann-Laband syndrome 3 is associated with mutations in the KCNN3 gene on chromosome 1.
KCNN3 is classified as a druggable target (Druggable Genome and Ion Channel categories) with score 3.3.
Genetic testing for KCNN3 is available. Testing is considered confirmatory for diagnosis.
Phenotype severity distribution: 3 always present features, 20 common features.
No clinical trials have been registered for Zimmermann-Laband syndrome 3.
5 publications have been identified in PubMed for Zimmermann-Laband syndrome 3. Research spans Case Report / Case Series (40%), Basic Science / Preclinical (40%), and Review / Meta-Analysis (20%).
Sechi S (2025). [PMID: 41040851](https://pubmed.ncbi.nlm.nih.gov/41040851/). *Brain Commun*. [Basic Science / Preclinical]
Davenport M (2025). [PMID: 40519534](https://pubmed.ncbi.nlm.nih.gov/40519534/). *World J Pediatr Surg*. [Review / Meta-Analysis]
Carpentieri G (2024). [PMID: 39210597](https://pubmed.ncbi.nlm.nih.gov/39210597/). *HGG Adv*. [Case Report / Case Series]
Chen D (2024). [PMID: 38372889](https://pubmed.ncbi.nlm.nih.gov/38372889/). *Hum Cell*. [Basic Science / Preclinical]
Gu Y (2024). [PMID: 39087232](https://pubmed.ncbi.nlm.nih.gov/39087232/). *J Clin Pediatr Dent*. [Case Report / Case Series]
Data assembled from 5 of 12 sources · Last updated Sep 20, 2026, 3:05 PM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
Common questions about Zimmermann-Laband syndrome 3
Head and neck |
4 |
Coarse facial features, Facial hypertrichosis, High palate |
Muscles | 2 | Flexion contracture, Generalized hypotonia |
Brain and nerves | 2 | Intellectual disability, Global developmental delay |
Skin | 1 | Small nail |
Bones and joints | 1 | Excessive outward curvature of the upper spine (kyphosis) |
Age of onset: newborn period.